Fishy links: Killer B cells and evolution
27 September, 2006 by External Press Release AuthorResearchers from the University of Pennsylvania School of Veterinary Medicine have discovered a unique evolutionary link between the immune systems of fish and mammals in the form of a primitive version of B cells, white blood cells of the immune system.
Here we go again: what next for stem cells?
21 September, 2006 by Kate McDonaldWith developments in the embryonic stem cell debate changing as quickly as Melbourne's weather, Kate McDonald asked two of Australia's leading researchers - Stephen Livesey and Bernie Tuch - what would happen should the recommendations of the Lockhart Review be implemented.
Opinion: It's time to accept probiotics as scientifically proven therapeutic agents
21 July, 2006 by Ron PennyLeading immunologist Professor Ron Penny was so impressed with the potential of a proprietary probiotic, he joined the company.
SCS, Chemicon launch ES cell products
02 March, 2006 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) and Californian-based Chemicon are set to launch a new product line of culture media for mouse embryonic stem cells.
Scientists find new way to detect abnormal stem cells
27 February, 2006 by Ruth BeranMelbourne scientists have identified a new method of detecting abnormal embryonic stem (ES) cells before they change into cancerous cells.
Replikun contracts UK company to make GMP cell line
21 February, 2006 by Ruth BeranUnlisted immunotherapy company Replikun Biotech has contracted UK-based Cobra Biomanufacturing to build a cell line to manufacture their vaccine and immunotherapy products under GMP conditions.
$6.5m in grants to bird flu projects
20 February, 2006 by Staff WritersThe Commonwealth government has outlined AUD$6.5 million in urgent funding for 33 research projects aiming to prevent, detect or control avian influenza and other respiratory disease outbreaks.
CSL plots its future course with R&D
20 February, 2006 by Graeme O'NeillTo no one's surprise, CSL has become the dominant force in the Australian biotechnology sector. Graeme O'Neill learns from CSL's chief scientist, Andrew Cuthbertson, about the solid research that will drive the company in the next few years.
Dairy CRC develops new stem cell techniques
15 February, 2006 by Ruth BeranScientists at the Dairy Cooperative Research Centre (CRC) have discovered new methods to isolate and maintain large numbers of bovine embryonic stem cells.
Garvan spin-off in $137m anti-inflammatory deal
08 February, 2006 by Helen SchullerG2 Therapies, a spin-off company from Sydney's Garvan Institute of Medical Research, has signed a licensing agreement worth up to AUD$137 million with Denmark's Novo Nordisk to develop, manufacture and commercialise new anti-inflammatory therapies based on G2's C5a receptor antibodies.
Mesoblast implants two with adult stem cells
06 February, 2006 by Ruth BeranThe first two patients in Melbourne-based Mesoblast's (ASX:MSB) clinical trials have been implanted with adult stem cells.
Stem Cell Sciences in new Scottish pact
01 February, 2006 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has signed a new tech transfer agreement with the University of Edinburgh, building on a formal collaboration begun in 1994.
CyGenics to open cord blood bank in India
23 January, 2006 by Ruth BeranSingapore-based, ASX-listed cell therapy company CyGenics (ASX:CYN) is the majority shareholder in a new Indian cord blood banking company, to be called CordLife Sciences (India), after an initial investment of AUD$850,000.
Sydney team patents new ES cell growth method
23 January, 2006 by Graeme O'NeillA research team at Sydney's Prince of Wales Hospital has developed and patented a technique for growing human embryonic stem (ES) cells without using animal-derived feeder cells.
US vaccine firm plans ASX listing
20 January, 2006 by Helen SchullerUS-based private vaccine development company Vaccinoma is planning to raise AUD$15 million through an IPO on the ASX in early April.
